ClinicalTrials.gg

Program

saroglitazar

Also written as “Saroglitazar Magnesium 1 mg”, “Saroglitazar Magnesium 2 mg” and “Saroglitazar Magnesium 4 mg”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Liver Cirrhosis, Biliary · Fibrosis · Renal Insufficiency · Dyslipidemias, led by Zydus Lifesciences.

Furthest: phase 4, since May 13, 202319 company-led studies, 6 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zydus Lifesciences196 open or runningphase 4since May 13, 2023Feb 7, 2017Dec 31, 2026phase 1 · NCT05045482

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Feb 7, 2017.

  1. Feb 24, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT03863574 · 16 enrolled · United States
  2. Aug 1, 2019Phase 1 study in HealthyNCT04045769 · 52 enrolled · India
  3. Sep 11, 2019Phase 1 study in HealthyNCT04112446 · 8 enrolled · United States
  4. Jun 15, 2020Phase 1 study in Renal InsufficiencyNCT04446507 · 32 enrolled · United States
  5. Jul 9, 2020Phase 1 study in Hepatic ImpairmentNCT04469920 · 98 enrolled · United States
  6. Jul 11, 2021Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT05011305 · 189 enrolled · United States, Argentina, Puerto Rico and more
  7. Jul 25, 2021Phase 1 study in FibrosisNCT05045482 · 30 planned · United States
  8. Nov 1, 2021Phase 3 study in Liver Cirrhosis, BiliaryNCT05133336 · 196 enrolled · United States, Argentina, Iceland and more
  9. Jan 24, 2022Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT05211284 · 4 enrolled · United States
  10. May 13, 2023Phase 4 study in Non-alcoholic Fatty Liver DiseaseNCT05872269 · 1,500 planned · India
  11. May 9, 2024Phase 3 study in Liver Cirrhosis, BiliaryNCT06427395 · 102 enrolled · United States, Argentina, Turkey (Türkiye)
  12. Feb 9, 2025Phase 1 study in Liver Cirrhosis, BiliaryNCT06825559 · 6 planned · United States
  13. Oct 5, 2025Phase 3 study in Liver Cirrhosis, BiliaryNCT07216235 · 386 planned · United States
  14. Dec 26, 2025Phase 3 study in Liver Cirrhosis, BiliaryNCT07424677 · 90 planned · United States

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Liver Cirrhosis, BiliaryNCT06825559
  2. Dec 31, 2026Primary completion: phase 1 study in FibrosisNCT05045482
  3. Apr 18, 2027Primary completion: phase 3 study in Liver Cirrhosis, BiliaryNCT06427395
  4. Jul 2028Primary completion: phase 3 study in Liver Cirrhosis, BiliaryNCT07424677

TargetBeta

PPARA →PPARG →read by rule
“Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
chiglitazarruleChipscreen Biosciencesphase 39
lanifibranorinventiva-pharmaphase 36

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07424677Liver Cirrhosis, Biliary · United States3RecruitingJul 202890
NCT07216235Liver Cirrhosis, Biliary · United States3RecruitingNov 2032386
NCT06825559Liver Cirrhosis, Biliary · United States1RecruitingDec 31, 20266
NCT06427395Liver Cirrhosis, Biliary · United States, Argentina, Turkey (Türkiye)3Active, not recruitingApr 18, 2027102
NCT05872269Non-alcoholic Fatty Liver Disease · India4RecruitingJan 10, 20251,500
NCT05211284Non-alcoholic Fatty Liver Disease · United States2TerminatedOct 2, 20234
NCT05133336Liver Cirrhosis, Biliary · United States, Argentina, Iceland and more3CompletedApr 30, 2025196
NCT05045482Fibrosis · United States1RecruitingDec 31, 202630
NCT05011305Non-alcoholic Fatty Liver Disease · United States, Argentina, Puerto Rico and more2CompletedSep 12, 2025189
NCT04469920Hepatic Impairment · United States1CompletedMar 21, 202298
NCT04446507Renal Insufficiency · United States1CompletedMay 28, 202432
NCT04112446Healthy · United States1CompletedOct 29, 20198
NCT04045769Healthy · India1CompletedNov 27, 201952
NCT03863574Non-alcoholic Fatty Liver Disease · United States2CompletedMar 20, 202016
NCT03639623Non-alcoholic Fatty Liver Disease · United States2CompletedDec 13, 202120
NCT03617263Non-alcoholic Fatty Liver Disease · United States, Mexico2TerminatedOct 28, 202460
NCT03112681Liver Cirrhosis, Biliary · United States2CompletedAug 7, 202037
NCT03097107Dyslipidemias · United States2SuspendedDec 2023124
NCT03061721Non-alcoholic Fatty Liver Disease · United States2CompletedAug 22, 2019106

How it is read

Names in the registry

  • “Saroglitazar Magnesium 1 mg”, 6 entries
  • “Saroglitazar Magnesium 2 mg”, 5 entries
  • “Saroglitazar Magnesium 4 mg”, 4 entries
  • “Saroglitazar magnesium 1 mg”, 2 entries
  • “Saroglitazar”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.